tbuckley/cabot-search huggingface dataset:
The E3 ligase VHL controls alveolar macrophage function via metabolic–epigenetic regulation
Authors: Wen Zhang, Qian Li, Dulei Li, Jia Li, Daisuke Aki, Yun-Cai Liu
Journal: The Journal of Experimental Medicine (2018)

Metabolic pathways such as glycolysis or oxidative phosphorylation play a key role in regulating macrophage function during inflammation and tissue repair. However, how exactly the VHL–HIF–glycolysis axis is involved in the function of tissue-resident macrophages remains unclear. Here we demonstrate that loss of VHL in myeloid cells resulted in attenuated pulmonary type 2 and fibrotic responses, accompanied by reduced eosinophil infiltration, decreased IL-5 and IL-13 concentrations, and ameliorated fiber deposition upon challenge. VHL deficiency uplifted glycolytic metabolism, decreased respiratory capacity, and reduced osteopontin expression in alveolar macrophages, which impaired the function of type 2 innate lymphoid cells but was significantly reversed by HIF1α inhibition or ablation. The up-regulated glycolysis altered the epigenetic modification of osteopontin gene, with the metabolic intermediate 3-phosphoglyceric acid as a key checkpoint controller. Thus, our results indicate that VHL acts as a crucial regulatory factor in lung inflammation and fibrosis by regulating alveolar macrophages.
Characterization of Recurrent Strokes With and Without Patent Foramen Ovale Closure
Authors: Scott E. Kasner, Carlos S. Kase, Tanya N. Turan, Howard A. Rowley, Grethe Andersen, Helle K. Iversen, Risto O. Roine, Steven R. Messé, John Volpi, Lars Søndergaard, John F. Rhodes, Christina Sjöstrand
Journal: Journal of the American College of Cardiology (2018)
Association of Prenatal Exposures of Polybrominated Diphenyl Ethers With Hypospadias
Authors: Chih-Chia Chen, Chi-Nien Chen
Journal: JAMA Pediatrics (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Abstract 19457: Cardioprotective Effects of the Novel Mitochondrial-Derived Peptide, Humanin, in a Porcine Model of Myocardial Ischemia-Reperfusion Injury
Authors: Chelsea L Organ, Murtuza J Ali, Amy Scarborough, Amanda Rushing, Sarah Boisvert, Zhenwei Gong, David J Lefer, Radhika Muzumdar, Traci T Goodchild
Journal: Circulation (2016)

Background: Humanin, a novel mitochondria-associated peptide, has previously been shown to exert potent cytoprotective and anti-apoptotic effects in rodent models of myocardial ischemia/reperfusion...
First china-manufactured proposed rituximab biosimilar met primary efficacy and safety endpoints in CD20-positive diffuse large B-cell lymphoma (generics)
Authors: Y. Shi, Q. Zhang, X. Han, Y. Song, Y. Qin, X. Hong, X. Ke, J. Feng, D. Wang, W. Li, H. Su, Y. Zhang, H. Zhang, J. Yang, L. Liu, X. Zhang, E. Liu, W. Jiang, S. Liu, A. Luk
Journal: Annals of Oncology (2018)
Abstract 14873: Atrial Fibrillation and Functional Mitral Regurgitation in Cardiac Resynchronisation Therapy
Authors: Pieter van der Bijl, Ngoc Mai Vo, Melissa Leung, Nina Ajmone Marsan, Victoria Delgado, Jeroen J Bax
Journal: Circulation (2017)

Introduction: Atrial fibrillation (AF) is a well-recognised cause of left atrial (LA) enlargement, which is associated with mitral annular dilation. This may result in atrial functional mitral regurgitation (AFMR). The purpose of this study was to evaluate the role of AFMR in cardiac resynchronization therapy (CRT) recipients with AF. Hypothesis: Evolution of functional mitral regurgitation (FMR) in CRT recipients is impacted by AFMR. This in turn, is mediated by LA enlargement and/or mitral annular remodeling, which is caused by AF. Methods: CRT recipients with heart failure, AF and sinus rhythm (SR) with moderate or severe FMR, were included from an ongoing registry. LA, mitral annular and left ventricular (LV) dimensions were evaluated with echocardiography. Improvement in FMR (quantified with a multiparametric approach) was defined as ≥1 grade decrease from baseline to 6 months’ follow-up. Clinical and echocardiographic measurements were performed at baseline and at 6 months’ follow-up. Results: A tot...
PD-L1 expression on circulating monocytes in patients with breast cancer
Authors: M. Nagano, K. Saito, Y. Kozuka, M. Shibusawa, N. Imai, A. Noro, Y. Kageyama, T. Mizuno, T. Ogawa, N. Katayama
Journal: Annals of Oncology (2018)

Background: Programmed death-ligand 1 (PD-L1) expression on tumor cells has been found to predict the response to immune checkpoint inhibitors in various cancers. PD-L1 is upregulated not only in tumor cells, but also in immune cells, such as macrophages in the tumor microenvironment. It is known that macrophages differentiate from monocytes. However, there are no data about PD-L1 expression in monocytes from patients with cancer. Whether PD-L1 expression on monocytes could serve as an alternative biomarker is of great interest. Methods: We prospectively collected peripheral blood mononuclear cells from 44 untreated patients with primary breast cancer from stage I to IV between 2016 and 2018. Flow cytometry was used to detect PD-L1 expression on monocytes. Results: We found that the level of PD-L1 expression on monocytes increased from patients with primary breast cancer (the median of PD-L1 stained cells was 14.0% (2.6-41.2) vs. isotype control of 1.0% (0.1-11.7), p < 0.001). The median proportions of PD-L1+ monocytes in patients with stage I, II, III, and IV cancers were 7.8% (2.6-35.5), 17.9% (4.3-41.2), 16.7% (9.6-25.9), and 25%, respectively. In lymph-node metastasis negative and positive patients, the proportions were 10.9% (2.6-41.2) and 17.9% (4.3-27.3), respectively. There were no significant differences among each stage nor between groups. However, early stages of breast cancers tended to have a lower proportion of PD-L1+ monocytes. In contrast, we observed that there was no trend between PD-L1 expression and the subtypes: HR+, 17.9% (2.6-41.2); HER2+, 16.7% (7.7-25.9); or TN, 10.7% (4.3-33.2). In addition, there was no significant correlation between the proportion of PD-L1+ monocytes and Ki-67 index (p = 0.94) of tumor cells nor %tumor infiltrating lymphocytes (TILs) (p = 0.83) in primary tumors. Conclusions: We found upregulated PD-L1 levels in monocytes in untreated patients with breast cancer. The proportions of PD-L1+ cells tend to increase depending on disease progression. In contrast, there was no association between PD-L1+ cells and subtypes, proliferative index, or %TILs. These data suggest that PD-L1 expression on circulating monocytes may reflect tumor burden rather than tumor biology. Legal entity responsible for the study: Mie University Hospital. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.
Central Nervous System Fungal Infections in Children with Leukemia, Risk Factors and Outcome: A Multicentric Study
Authors: Rejin Kebudi, Serap Karaman, Hande Kizilocak, Zeynep Karakas, Melike Sezgin Evim, Bengü Demirag, Zuhre Kaya, Husniye Nese Yarali, Umran Caliskan, B.Sahin Karagun, Canan Albayrak, Sebnem Yilmaz, Deniz Karapinar, Ekrem Unal, Adalet Meral Gunes, Neryal Tahta, Zeliha Guzelkucuk, Ulker Kocak, Tiraje Celkan
Journal: Blood (2018)
Cervical esophageal adenocarcinoma arising from heterotopic gastric mucosa, treated with endoscopic submucosal dissection
Authors: Yasuhiro Oono, Shinmura Kensuke, Yusuke Yoda, Keisuke Hori, Hiroaki Ikematsu, Tomonori Yano
Journal: Endoscopy (2018)

Esophageal adenocarcinoma arising from heterotopic gastric mucosa (HGM) is extremely rare [1] [2]. We describe a case of esophageal adenocarcinoma arising from HGM in the cervical esophagus that was treated with endoscopic submucosal dissection (ESD).
Abstract 14035: Small Left Ventricle is Risk Factor For Mortality After Axial-flow (Heartmate II) Implantation
Authors: Masashi Kawabori, Chitaru Kurihara, Tadahisa Sugiura, Gabriel Loor, Andrew B Civitello, Reynolds M Delgado, O H Frazier, Jeffrey A Morgan
Journal: Circulation (2017)

Introduction: The effects of having a preoperative small left ventricle (LV) in patients undergoing HeartMate II (HM-II) implantation remains unclear. Methods: We analyzed our single-center data in...
Pacritinib in Patients With Myelofibrosis
Authors: Shotaro Suzuki, Kenji Tsuda, Tetsuya Tanimoto
Journal: JAMA Oncology (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Proteinase-activated receptor 1 antagonism ameliorates experimental pulmonary hypertension
Authors: Yukimitsu Kuwabara, Mariko Tanaka-Ishikawa, Kohtaro Abe, Mayumi Hirano, Yoshitaka Hirooka, Hiroyuki Tsutsui, Kenji Sunagawa, Katsuya Hirano
Journal: Cardiovascular Research (2018)

Pulmonary hypertension (PH) is characterized by progressive increases in pulmonary vascular resistance (PVR). Thrombotic lesions are common pathological findings. The pulmonary artery has a unique property regarding the vasoconstrictive response to thrombin, which is mediated by proteinase-activated receptor 1 (PAR1). We aim to elucidate the role of PAR1 in the development and progression of PH. A rat model of monocrotaline-induced PH and a mouse model of hypoxia (Hx)-induced PH were used to investigate the effects of atopaxar (a PAR1 antagonist) and PAR1 knockout on haemodynamic parameters, right ventricular hypertrophy (RVH), vascular remodelling and survival. In perfused lung preparations, the pressor response to PAR1 agonist was significantly augmented in monocrotaline-induced PH. Both the preventive and therapeutic administration of atopaxar significantly inhibited the increase in PVR and the development of RVH and prolonged survival. A real-time PCR revealed that the level of PAR1 mRNA in the pulmonary artery was significantly higher than that in any of the systemic arteries examined in control rats, and the level was significantly up-regulated in monocrotaline-induced PH. PAR1 gene knockout significantly attenuated the haemodynamic and histological findings in the mouse model of Hx-induced PH. The specific expression of PAR1 in the pulmonary artery and its up-regulation were suggested to play a critical role in the development and progression of experimental PH in murine models. PAR1 is a potential therapeutic target for the treatment of PH.
Economic and Quality-of-Life Outcomes of Natriuretic Peptide–Guided Therapy for Heart Failure
Authors: Daniel B. Mark, Patricia A. Cowper, Kevin J. Anstrom, Shubin Sheng, Melanie R. Daniels, J. David Knight, Khaula N. Baloch, Linda Davidson-Ray, Mona Fiuzat, James L. Januzzi, David J. Whellan, Ileana L. Piña, Justin A. Ezekowitz, Kirkwood F. Adams, Lawton S. Cooper, Christopher M. O’Connor, G. Michael Felker
Journal: Journal of the American College of Cardiology (2018)
A Potent Tumor-Reactive p53-Specific Single-Chain TCR without On- or Off-Target Autoimmunity In Vivo
Authors: Hakim Echchannaoui, Jutta Petschenka, Edite Antunes Ferreira, Beate Hauptrock, Carina Lotz-Jenne, Ralf-Holger Voss, Matthias Theobald
Journal: Molecular Therapy (2018)

Genetic engineering of T cells with a T cell receptor (TCR) targeting tumor antigen is a promising strategy for cancer immunotherapy. Inefficient expression of the introduced TCR due to TCR mispairing may limit the efficacy and adversely affect the safety of TCR gene therapy. Here, we evaluated the safety and therapeutic efficiency of an optimized single-chain TCR (scTCR) specific for an HLA-A2.1-restricted (non-mutated) p53(264–272) peptide in adoptive T cell transfer (ACT) models using our unique transgenic mice expressing human p53 and HLA-A2.1 that closely mimic the human setting. Specifically, we showed that adoptive transfer of optimized scTCR-redirected T cells does not induce on-target and off-target autoimmunity. Furthermore, ACT resulted in full tumor protection and led to a long-lived effective, antigen-specific memory T cell response in syngeneic and xenograft models. Taken together, the study demonstrated that our scTCR specific for the broadly expressed tumor-associated antigen p53(264–272) can eradicate p53+A2.1+ tumor cells without inducing off-target or self-directed toxicities in mouse models of ACT. These data strongly support the improved safety and therapeutic efficacy of high-affinity p53scTCR for TCR-based immunotherapy of p53-associated malignancies. Genetic engineering of T cells with a T cell receptor (TCR) targeting tumor antigen is a promising strategy for cancer immunotherapy. Inefficient expression of the introduced TCR due to TCR mispairing may limit the efficacy and adversely affect the safety of TCR gene therapy. Here, we evaluated the safety and therapeutic efficiency of an optimized single-chain TCR (scTCR) specific for an HLA-A2.1-restricted (non-mutated) p53(264–272) peptide in adoptive T cell transfer (ACT) models using our unique transgenic mice expressing human p53 and HLA-A2.1 that closely mimic the human setting. Specifically, we showed that adoptive transfer of optimized scTCR-redirected T cells does not induce on-target and off-target autoimmunity. Furthermore, ACT resulted in full tumor protection and led to a long-lived effective, antigen-specific memory T cell response in syngeneic and xenograft models. Taken together, the study demonstrated that our scTCR specific for the broadly expressed tumor-associated antigen p53(264–272) can eradicate p53+A2.1+ tumor cells without inducing off-target or self-directed toxicities in mouse models of ACT. These data strongly support the improved safety and therapeutic efficacy of high-affinity p53scTCR for TCR-based immunotherapy of p53-associated malignancies.
Stimulating brain recovery after stroke using theranostic albumin nanocarriers loaded with nerve growth factor in combination therapy
Authors: Tivadar Feczkó, Albrecht Piiper, Saema Ansar, Frank W. Blixt, Mukul Ashtikar, Susanne Schiffmann, Thomas Ulshöfer, Michael J. Parnham, Yifat Harel, Liron Limor Israel, Jean-Paul Lellouche, Matthias G. Wacker
Journal: Journal of Controlled Release (2018)
Prognostic Value of RANKL/OPG Serum Levels and Disseminated Tumor Cells in Nonmetastatic Breast Cancer
Authors: Tilman D. Rachner, Sabine Kasimir-Bauer, Andy Göbel, Kati Erdmann, Oliver Hoffmann, Andrew Browne, Pauline Wimberger, Martina Rauner, Lorenz C. Hofbauer, Rainer Kimmig, Ann-Kathrin Bittner
Journal: Clinical Cancer Research (2018)

We assessed serum concentrations of the receptor activator of NFκB ligand (RANKL) and its decoy receptor, osteoprotegerin (OPG), two proteins implicated in the development and progression of breast cancer, in 509 patients with primary, nonmetastatic breast cancer. Then the results were evaluated with regards to the occurrence of bone metastases, the presence of disseminated tumor cells (DTC) in the bone marrow, survival, and risk of developing metastatic disease.Before surgery, two bone marrow aspirates were analyzed for DTC using density centrifugation followed by immunocytochemistry (pan-cytokeratin antibody A45-B/B3). RANKL and OPG levels in the serum were measured by ELISA.RANKL levels were significantly lower in women >60 years (P < 0.0001) and RANKL/OPG ratios higher in lymph node-positive patients (P < 0.05). High OPG serum levels were associated with a higher risk of death from breast cancer [HR 1.94; 95% confidence interval (CI) 1.23-3.07; P = 0.005] and OPG was an independent prognostic marker for breast cancer-specific survival (BCSS; multivariate analyses, P = 0.035). RANKL levels were 33% higher (P < 0.0001) in DTCpos patients (41%), whereas high levels were associated with a significantly better BCSS in DTCneg patients as compared with low levels (HR 0.524; 95% CI 0.30-0.95; P = 0.04). RANKL serum levels were significantly increased in patients who developed bone metastases (P = 0.01) and patients within the highest quartile of RANKL had a significantly increased risk of developing bone metastases compared with those in the lowest (HR 4.62; 95% CI 1.49-14.34; P = 0.03).These findings warrant further investigation as they provide a rationale for novel diagnostic or therapeutic approaches.
A randomized, phase II, multicenter, open-label study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing gastric cancer
Authors: K. Shitara, Y.-J. Bang, D. Sakai, H. Yasui, Y. Kawaguchi, M. Sugihara, K. Saito, R. Dalal, K. Yamaguchi
Journal: Annals of Oncology (2018)
Review of American Society for Bioethics and Humanities' Clinical Ethics Consultation Affairs Committee, <i>Addressing Patient-Centered Ethical Issues in Health Care: A Case-Based Study Guide<sup>1</sup></i>
Authors: Joseph B. Fanning
Journal: The American Journal of Bioethics (2018)

"Review of American Society for Bioethics and Humanities' Clinical Ethics Consultation Affairs Committee, Addressing Patient-Centered Ethical Issues in Health Care: A Case-Based Study Guide1." The American Journal of Bioethics, 18(2), pp. W1–W2
Abstract 13846: Factor Xa Inhibition Prevents Cardiac Remodeling Induced by Intermittent Hypoxia in Sleep Apnea Model Mice
Authors: Fumi Yoshimura, Shota Tanikawa, Shogo Hosako, Ryuji Kato, Yoshio Ijiri, Yasukatsu Izumi, Minoru Yoshiyama, Tetsuya Hayashi
Journal: Circulation (2015)

Introduction: We have reported that intermittent hypoxia (IH) relevant to sleep apnea increases oxidative stress causing vascular remodeling and heart failure. The serine protease factor Xa in the coagulation cascade elicits inflammatory responses in endothelial cells. Hypothesis: We hypothesize that rivaroxaban might attenuate cardiac remodeling induced by IH in sleep apnea model mice. Methods: Male C57BL/6J mice at 8 weeks of age were exposed to IH (repeated cycles of 1.5 minute of 5% oxygen followed by 5 minutes of 21% oxygen) for 56 days with/without treatment by rivaroxaban (1.2 g riv./kg chow). After echocardiography, heart was examined by light and electron microscopy, immunohistochemistry, and RT-PCR. HPAECs were cultured under hypoxic conditions (37%, 1% O 2 , 5% CO 2 ) with/without rivaroxaban (1 μM). Results: IH caused cardiac remodeling (Figure), associated with both systolic and diastolic dysfunction compared with those of normoxia (IH vehicle vs. Normoxia; EF: 51.8% vs. 59.4% and E/e’: 29.4 vs. 22.3), which were attenuated by rivaroxaban (EF: 55.8%, E/e’: 24.6). In right atrial myocardium, IH caused endothelial cell degeneration, dissociation of intercalated discs, vacuolar formation and loss of ANP specific granules. Furthermore, 4-hydroxy-2-nonenal protein adducts and the expression of protease-activated receptor-1 (PAR-1) and NF-kB mRNA were increased by IH. Treatment with rivaroxaban significantly suppressed PAR-1 and NF-kB mRNA expression, increased ANP granules and reduced perivascular fibrosis, preventing cardiac remodeling due to IH. Conclusions: Rivaroxaban may attenuate atrial and ventricular remodeling induced by IH at least partly through its anti-inflammatory effect in sleep apnea model mice.
Sequencing Therapy for Elderly Chronic Lymphocytic Leukemia Patients in the Era of Novel Therapies: An Overview of Randomized Clinical Trials
Authors: Malik Qistas Ahmad, Chaudhry Saad Sohail, Muhammad Yasir, Muhammad Junaid Tariq, Arshia Akbar, Muhammad Jahanzeb Khalil, Muhammad Usman, Muhammad Asad Fraz, Muhammad Umair Jahngir, Ali Younas Khan, Awais Ijaz, Ceren Durer, Seren Durer, Faiz Anwer
Journal: Blood (2018)
A propensity score-matched comparison of laparoscopic distal versus total gastrectomy for middle-third advanced gastric cancer
Authors: Wen-Jie Wang, Hong-Tao Li, Peng Chen, Jian-Ping Yu, Zuo-Yi Jiao, Xiao-Peng Han, Lin Su, Rui-Yu Tao, Lin Xu, Yan-Long Kong, Yu-Min Li, Hong-Bin Liu
Journal: International Journal of Surgery (2018)
Expansion of the Medicare 340B Payment Program
Authors: Peter B. Bach, Rachel E. Sachs
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Endothelial Dysfunction and Platelet Activation in Major Depressive Disorder: Association with Brain Perfusion Abnormalities
Authors: Jaime Pereira, Teresa Massardo, Claudia G Saez, Nixa Olivares, Jose G Valenzuela, Luis Risco, Jonathan Veliz, Jane Spuler, Gabriel Castro, Ellieth Falloux, Carolina Villa, Juan C Quintana, Daniel Vicentini, Diego Mezzano
Journal: Blood (2018)